CYP2C19Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?
出版年份 2014 全文链接
标题
CYP2C19Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?
作者
关键词
-
出版物
PHARMACOTHERAPY
Volume 34, Issue 7, Pages 703-718
出版商
Wiley
发表日期
2014-02-08
DOI
10.1002/phar.1400
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A Pharmacogenetics Service Experience for Pharmacy Students, Residents, and Fellows
- (2013) Katarzyna Drozda et al. AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
- (2013) S A Scott et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Correlation of CYP2C19 Phenotype With Voriconazole Plasma Concentration in Children
- (2013) Atsushi Narita et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Gene sequencing leaves the laboratory
- (2013) Erika Check Hayden NATURE
- Institutional Profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics
- (2013) Julie A Johnson et al. PHARMACOGENOMICS
- Voriconazole Serum Concentrations in Obese and Overweight Immunocompromised Patients: A Retrospective Review
- (2013) Samantha Davies-Vorbrodt et al. PHARMACOTHERAPY
- Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring
- (2012) Michael J. Dolton et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Septic Shock Attributed to Candida Infection: Importance of Empiric Therapy and Source Control
- (2012) M. Kollef et al. CLINICAL INFECTIOUS DISEASES
- The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial
- (2012) Wan Beom Park et al. CLINICAL INFECTIOUS DISEASES
- Editorial Commentary: Antifungal Therapeutic Drug Monitoring Progress: Getting It Right the First Time
- (2012) D. Andes et al. CLINICAL INFECTIOUS DISEASES
- Challenging Recommended Oral and Intravenous Voriconazole Doses for Improved Efficacy and Safety: Population Pharmacokinetics–Based Analysis of Adult Patients With Invasive Fungal Infections
- (2012) Andres Pascual et al. CLINICAL INFECTIOUS DISEASES
- Implementing Personalized Medicine: Development of a Cost-Effective Customized Pharmacogenetics Genotyping Array
- (2012) J A Johnson et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The 1200 Patients Project: Creating a New Medical Model System for Clinical Implementation of Pharmacogenomics
- (2012) P H O'Donnell et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory
- (2012) Charles M. Strom et al. GENETICS IN MEDICINE
- Cost-Effectiveness of Cytochrome P450 2C19 Genotype Screening for Selection of Antiplatelet Therapy with Clopidogrel or Prasugrel
- (2012) Emily S. Reese et al. PHARMACOTHERAPY
- The Development of Appropriate Dosage of Anti-bacterial and Anti-fungal Agents Based on Pharmacokinetics and Pharmacodynamics
- (2012) Kazuaki Matsumoto YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN
- Development and implementation of a pharmacist-managed clinical pharmacogenetics service
- (2011) K. R. Crews et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients
- (2011) Peter F. Troke et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics
- (2011) H R Ashbee et al. BONE MARROW TRANSPLANTATION
- A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepine
- (2011) Mirte M. Malingré et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacogenetics: From Bench to Byte— An Update of Guidelines
- (2011) J J Swen et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients
- (2011) Si-Hyun Kim et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers
- (2011) SeungHwan Lee et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction
- (2011) Brad Moriyama et al. MYCOSES
- Pharmacogenomics of the triazole antifungal agent voriconazole
- (2011) Gerd Mikus et al. PHARMACOGENOMICS
- Modulators of Very Low Voriconazole Concentrations in Routine Therapeutic Drug Monitoring
- (2011) Arwa Hassan et al. THERAPEUTIC DRUG MONITORING
- Voriconazole Pharmacokinetics and Safety in Immunocompromised Children Compared to Adult Patients
- (2010) C. Michael et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients
- (2010) Maud Berge et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism
- (2010) Hui-Yan Shi et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Lack of Effect of Ginkgo biloba on Voriconazole Pharmacokinetics in Chinese Volunteers Identified as CYP2C19 Poor and Extensive Metabolizers
- (2009) He-Ping Lei et al. ANNALS OF PHARMACOTHERAPY
- Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype
- (2009) Ina Scholz et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
- (2009) Alain Li-Wan-Po et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- How Many Steps along the Path Is Too Far?
- (2009) G. L. Drusano CLINICAL INFECTIOUS DISEASES
- Voriconazole Pharmacokinetics and Pharmacodynamics in Children
- (2009) Michael Neely et al. CLINICAL INFECTIOUS DISEASES
- Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes
- (2009) Kazuaki Matsumoto et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders
- (2009) Koki Ueda et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population
- (2008) Katsuyoshi Sugimoto et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacogenetics: From Bench to Byte
- (2008) JJ Swen et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical Pharmacogenetics and Potential Application in Personalized Medicine
- (2008) Shu-Feng Zhou et al. CURRENT DRUG METABOLISM
- The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers
- (2008) Guo Wang et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- CYP2C19Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole
- (2008) Johanna Weiss et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes
- (2007) A. Pascual et al. CLINICAL INFECTIOUS DISEASES
- What Is the "Therapeutic Range" for Voriconazole?
- (2007) R. E. Lewis CLINICAL INFECTIOUS DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started